Canada markets closed

BriaCell Therapeutics Corp. (BCTX)

NasdaqCM - NasdaqCM Real Time Price. Currency in USD
Add to watchlist
10.06+0.08 (+0.80%)
At close: 04:00PM EST
10.00 -0.06 (-0.60%)
After hours: 07:56PM EST

BriaCell Therapeutics Corp.

Bellevue Centre
Suite 300 235 West 15th Street
West Vancouver, BC V7T 2X1
Canada

http://www.briacell.com

Sector(s)Healthcare
IndustryBiotechnology
Full Time Employees5

Key Executives

NameTitlePayExercisedYear Born
Dr. William V. Williams M.D.CEO, Pres & Director283.44kN/A1956
Dr. Charles Louis Wiseman FACP, M.D.Founder, Principal Advisor & Member of Scientific Advisory Board73.1kN/A1946
Mr. Gadi Levin B.Com., C.A., CPA, M.B.A., MBACFO & Corp. Sec.52.5kN/A1973
Ms. Farrah DeanMang. of Corp. Devel.N/AN/AN/A
Amounts are as of December 31, 2020 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

BriaCell Therapeutics Corp., an immuno-oncology biotechnology company, engages in developing immunotherapies for the treatment of cancer. Its lead candidate is Bria-IMT that is in Phase I/IIa clinical trial in a combination study with immune checkpoint inhibitors for the treatment of breast cancer. The company also has a cooperative research and development agreement with the National Cancer Institute for developing Bria-OTS, a personalized immunotherapy for advanced breast cancer; and BriaDx, a diagnostic test. BriaCell Therapeutics Corp. is headquartered in West Vancouver, Canada.

Corporate Governance

BriaCell Therapeutics Corp.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.